TABLE 1.

Patient characteristics.

Characteristics	Total number of patients (n = 236)
Sex
Male/female	189/47
Median age at treatment (years) (range)	68 (24–82)
Performance status
0/1/2/3/4	82/138/15/1/0
Smoking history
Yes/no	209/27
Clinical stage at diagnosis
II/III/IV/postoperative recurrence	1/9/178/48
Histology
Adenocarcinoma/others	216/20
PD‐L1 tumor proportion score (%)
<1/1–49/≥50/unknown	77/75/57/27
Driver gene mutation/translocation
EGFR/ALK/others/wild‐type, negative, or unknown a	5/0/27/204
History of postoperative adjuvant chemotherapy
Yes/no	33/203
Intracranial metastases at initial treatment
Yes/no	58/178
Liver metastases at initial treatment
Yes/no	12/224
Bone metastases at initial treatment
Yes/no	88/148
Body mass index (kg/m2)
Median (range)	22.2 (13.3–36.5)
Prior radiotherapy b
Yes/no	58/178
Number of cycles of platinum+pemetrexed+pembrolizumab administered
Median	4
Range	1–6
Number of cycles of maintenance therapy administered c
Median	3
Range	0–51
Platinum agent
Cisplatin/carboplatin	46/190
Reason for discontinuation of platinum + pemetrexed + pembrolizumab administration d
Progressive disease	28
Adverse events	39
Worsening of performance status	6
Others	9
Steroid treatment for adverse events e
Yes/no	63/173
Laboratory data, median (range)
C‐reactive protein (mg/dL)	0.70 (0.01–21.0)
Albumin (g/dL)	3.7 (1.7–4.8)
Neutrophil (cells/μL)	4718.5 (1200–23 360)
Lymphocyte (cells/μL)	1361 (285–3610)
Continuing administration of maintenance therapy at data cutoff	23

^a Test results showed no known genetic abnormalities such as EGFR mutations and ALK fusion genes, or no known genetic abnormalities had been tested for.

^b Curative intent and palliative radiotherapy.

^c Including pemetrexed + pembrolizumab, pemetrexed, or pembrolizumab maintenance therapy.

^d Excluding maintenance therapy.

^e Excluding topical agents.